drugset
drugset / Trial / NCT05514275

Radiotherapy Combined With Endostatin and Capecitabine for NPC

NCT05514275 ↗

Phase 2 Recruiting 41 enrolled Zhejiang Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

Radiotherapy combined with recombinant human endostatin and capecitabine for patients with nasopharyngeal carcinoma (NPC) resistant to induction chemotherapy.

Timeline

Start
2022-08-01
Primary completion
2026-08-01
Completion
2028-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 650 mg/m2 Oral
Subject Endostar Protein / enzyme biologic 37.5 mg/m2 Intravenous

Indications

nasopharyngeal carcinoma